Search
MDxHealth SA
MDXHAdd to Watchlist
0.411USD
+0.011+2.70%
Close 07-30 16:00（ET）Quotes delayed by 15 min
21.11MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-30The current earnings forecast score of MDxHealth SA is 8.33, ranking 137 out of 384 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 9.00 and a low of 4.20.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
2.800
Target Price
+569.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
MDxHealth SA
MDXH
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is MDxHealth SA's expected revenue for the next quarter?
MDxHealth SA's expected revenue is 25.88M.
What is MDxHealth SA's price target?
Analysts forecast that MDxHealth SA's price target is USD 7.00, with the highest forecast at USD 9.00 and the lowest forecast at USD 4.20.
How have MDxHealth SAMDXH's recent earnings per share performed?
The market expectation was USD -0.17, while MDxHealth SAMDXH's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.19.
What is the analyst rating for MDxHealth SA?
Based on the ratings of MDxHealth SA's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.